Better Therapeutics Announces Publication of Cost-Effectiven

Over a lifetime horizon AspyreRx plus standard of care was estimated to be superior to SoC alone providing more life years and improvements in quality of life at a lower cost


Study suggests that...

Related Keywords

United States , American , Niall Davison , Frank Karbe , Nasdaq , Exchange Commission , American Diabetes Association , Institute For Clinical , Senior Scientific Lead At Maple Health Group , Better Therapeutics Inc , Better Therapeutics , Effectiveness Analysis , Prescription Digital Therapeutic , Economic Review , Senior Scientific Lead , Maple Health , Better Therapeutic , Markets ,